Summary of Product Characteristics (A-C)
This document provides a concise summary of the key characteristics of an antipsychotic product, drawing information from regulatory bodies such as the FDA, EMA, and HPRA. This file includes the following antipsychotics: Amisulpride, Aripiprazole, Asenapine, Brexpiprazole, Cariprazine, Chlorpromazine, Clozapine
Summary of Product Characteristics (D-Z)
This document provides a concise summary of the key characteristics of an antipsychotic product, drawing information from regulatory bodies such as the FDA, EMA, and HPRA. This file includes the following antipsychotics: Haloperidol, Iloperidone, Lumateperone, Lurasidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Sertindole, Xanomeline and Trospium Chloride, Ziprasidone
DrugBank Interaction checker
Professional database tool for checking potential interactions between medications with comprehensive pharmaceutical information.
Drugs.com Interaction Checker
Comprehensive medication interaction checker allowing users to check for potential drug-drug and drug-food interactions.
Shared-Decision-Making Assistant (SDMA)
A Shared-Decision-Making Assistant for schizophrenia treatment that compares antipsychotic medications by efficacy and side effects (weight gain, movement disorders, etc.) to support collaborative treatment decisions.
PSYMATIK
Evidence-based psychiatry tools offering an algorithmic schizophrenia guideline (INTEGRATE), antipsychotic and antidepressant treatment optimizers to weigh side effects, and switching guides; delivers personalised treatment recommendations (free sign-up required).
Antipsychotics Dose Calculator (Excel File)
An Excel file for converting antipsychotic doses can be downloaded from the linked page.
metaconvert (Automated computations of effect sizes)
A tool for medication conversion calculations and dosage equivalencies.
WHO Daily-Defined-Doses (DDD)
WHO Defined Daily Dose (DDD) Lookup — search the official WHO ATC/DDD Index to find standardized DDDs for antipsychotics, antidepressants, and other medicines.
SwitchRx
Online psychotropic switching tool for clinicians: select the current and target antidepressant or antipsychotic to generate suggested cross-taper/titration schedules, with clinical tips, pharmacokinetic notes, and precautions; also supports transitions from monotherapy to combination regimens; registration required.
Serious Mental Illness Adviser
SMI Adviser (APA) — a clinical support system for serious mental illness offering free accredited education, evidence-based resources, and on-demand clinician-to-clinician consultations; access requires login (free account).
Serious Mental Illness Adviser - Long-Acting Injectable Antipsychotics
Clinician’s Guide to Preparing and Administering Long-Acting Injectable Antipsychotics — on-demand APA/SMI Adviser course that teaches clinicians how to discuss LAIs with patients, prepare/handle required supplies, identify IM/SC landmarks, and administer injections step-by-step
Psychoeducation for Schizophrenia (by Josef Bäuml, Irene Bighelli, and Stefan Leucht)
Comprehensive educational resource by Josef Bäuml, Irene Bighelli, and Stefan Leucht providing essential information for patients and caregivers. Download available as PowerPoint slides.
Metacognitive Training (MCT) Open Source
Metacognitive Training (MCT) Open Source — download editable developer versions of MCT for Psychosis and MCT+ (PowerPoint & Word) to adapt slides (e.g., culture-specific exercises/phrasing) for non-commercial use.
Relapse Risk vs. Antipsychotic Dose
Interactive tool showing dose-dependent relapse risk based on risperidone equivalents (Leucht 2021). Convert other antipsychotics using the included converter.
AGNP Therapeutic Drug Monitoring Guidelines (Therapeutic Plasma Reference Ranges)
Consolidated tables of therapeutic plasma reference ranges for 154 psychotropic and neurologic drugs (antipsychotics, antidepressants, mood stabilizers, antiepileptics), with methods to define lower/upper limits, dose-related reference ranges (C/D) to flag PK anomalies, and laboratory alert levels; recommends interpreting trough steady-state concentrations and lists when TDM is indicated.
Anticholinergic Burden Calculator (ABC)
Anticholinergic Cognitive Burden (ACB) Calculator — enter a medication list to sum per-drug anticholinergic scores (0–3) and automatically flag high risk at totals ≥3 (linked to confusion, falls, and higher mortality); includes a searchable Medicines Scorecard and practical options to reduce burden.
Fracture Risk Assessment
Fracture Risk Assessment Tool from the University of Sheffield used to evaluate the 10-year probability of fracture for patients.
Embryotox
Embryotox — Charité’s teratology/pharmacovigilance center with evidence-based monographs on 400+ medicines for use in pregnancy and breastfeeding; entries provide risk assessments, clinical recommendations and references, and may differ from package inserts; searchable by active substance. (German)
Early Warning Signs (ITAREPS)
Full 10-item scale in Table 1, with both Patient and Family-Member versions, including the exact item wording and a 0–4 response scale.
PANSS-BPRS-CGI Converter
Converts between different schizophrenia symptom rating scales (BPRS, PANSS, CGI) using equipercentile linking to standardize assessment scores across different clinical tools.
Neuroscience-based Nomenclature (NbN)
Neuroscience-based Nomenclature (NbN) — ECNP-led, pharmacology/mode-of-action classification of psychotropic medicines, developed with ACNP, CINP, AsCNP and IUPHAR; provides a searchable website and free apps (including Child & Adolescent and Patients & Families versions) to standardize drug naming and support rational prescribing; updated annually.
Illuminatum Living Information Center Now Online
The Technical University of Munich's Section for Evidence-Based Medicine in Psychiatry and Psychotherapy is pleased to announce the launch of Illuminatum, a Living Information Center for mental health professionals and...
Online community forum for people affected by schizophrenia to share experiences and find support.
Research initiative providing guidelines for healthcare providers and patients on safely reducing or stopping medications that may be harmful or no longer needed.
Open database for meta-analyses of psychological treatments and interventions with visualization tools.
Resource providing DSM-5 Text Revision treatment guidelines for psychiatric conditions.
The World Health Organization's ICD-11 classification system for mental, behavioral, and neurodevelopmental disorders (2024 version).
The Schizophrenia International Research Society (SIRS) - a worldwide organization bringing together researchers and clinicians in schizophrenia and related disorders.
Evidence-based resources and tools for mental health professionals from the Technical University of Munich, featuring medication calculators, decision-making assistants, and clinical guidelines for psychiatric practice.
The World Psychiatric Association is a global association representing 147 psychiatric societies in 123 countries, bringing together more than 250,000 psychiatrists to advance psychiatry and mental health worldwide.
The WFSBP is a non-profit, international organization composed of 64 national societies of biological psychiatry. Its principal objective is to foster and encourage scientific research and advancement in the field of biological psychiatry.
The International College of Neuropsychopharmacology (CINP) is a global organization dedicated to advancing worldwide neuroscience and education for brain and mental health by facilitating training and promoting research on a worldwide basis.
ECNP is a leading European scientific society dedicated to the science and treatment of disorders of the brain. It has specific "Networks" dedicated to fostering research collaboration, including the ECNP Schizophrenia Network, which brings together European researchers to advance the understanding and treatment of schizophrenia.
A leading online and print resource for psychiatrists and mental health professionals. It provides clinical articles, news on the latest research, conference coverage, and columns from leaders in the field.
Digital gateway for psychiatric knowledge, published by the American Psychiatric Association. It is an essential, integrated platform for clinicians, researchers, and trainees.
Consistently holds the highest impact factor of any psychiatric journal. It primarily publishes high-quality reviews, commentaries, and research articles with a global perspective, aiming to be directly relevant to clinicians worldwide.
Part of the prestigious Lancet family of journals, it publishes outstanding international clinical research that covers all aspects of psychiatry. It is known for high-impact original research, randomized controlled trials, systematic reviews, and influential commentaries.
A leading international journal for clinical and translational research in psychiatry, psychology, and behavioral science. It publishes novel, important, and rigorously designed studies on the causes, treatments, and prevention of mental and behavioral disorders.
As the official journal of the American Psychiatric Association (APA), it is the most widely read psychiatric journal in the United States and highly influential globally. It publishes major original research, in-depth reviews, and clinical case conferences across all areas of psychiatry.
The leading journal for research into the biological basis of psychiatric disorders. It specializes in studies on molecular genetics, neurobiology, psychopharmacology, and other basic science research that sheds light on the mechanisms of mental illness.
A premier journal focused on the broad field of biological psychiatry. It publishes novel research on the pathophysiology and treatment of major psychiatric disorders, covering a wide range of topics from neuroimaging and genetics to electrophysiology and pharmacology.
Developed by psychiatric experts, these guidelines provide evidence-based recommendations for the treatment of specific psychiatric disorders. They are considered the standard of care in the United States.
NICE guidelines are internationally renowned for their rigorous, evidence-based methodology, which includes clinical and economic analysis. They are highly influential in Europe and beyond and cover a wide range of mental health conditions.
These are expert-led, evidence-based consensus guidelines focused specifically on the use of medications in psychiatry. They are highly detailed and are a go-to resource for prescribers seeking in-depth psychopharmacological guidance.
The Mental Health Gap Action Programme (mhGAP) provides evidence-based guidelines for managing mental, neurological, and substance use disorders in non-specialized health settings. These are crucial for integrating mental healthcare into primary care, especially in low- and middle-income countries.
SIGN develops and disseminates evidence-based clinical practice guidelines for NHS Scotland. It is the Scottish equivalent of NICE in England and is highly respected for its rigorous methodology. Their guidelines are the standard for clinical practice within Scotland.
The DGPPN is Germany's largest scientific-medical association for mental health. They lead the development of high-quality, evidence-based national guidelines (called "S3-Leitlinien"). These are officially published and registered through the AWMF (Association of the Scientific Medical Societies in Germany), which hosts a central portal for all German medical guidelines.
Guideline for Pharmacological Therapy of Schizophrenia — developed by the Japanese Society of Neuropsychopharmacology, these open-access guidelines provide evidence-based recommendations across first-episode, acute, and maintenance phases, including antipsychotic selection, dosing intervals, long-acting injectables, switching strategies, and clozapine for treatment resistance. They are intended to support consistent, rational prescribing in Japan.
The Mental Elf - evidence-based mental health information service that provides summaries of research with "no bias, no misinformation, no spin."